OverviewSuggest Edit
BioNTech is a biopharmaceutical company developing therapies against cancer and infectious diseases. It provides peptide manufacturing services, GMP (good manufacturing practice) manufacturing services for mRNA and cell and gene therapies, and research services. The company also develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products through selected partners. BioNTech covers a range of platforms, including mRNA therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators.
| Type | Public | |
| Founded | 2008 | |
| HQ | Mainz, DE | Map |
| Website | biontech.de | |
| Employee Ratings | More |
Recent NewsAll News
- BioNTech, Pfizer to sell 40 million doses to lower-income countries
- Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19
- Pfizer and BioNTech will reportedly supply COVID-19 shots to COVAX, the WHO's vaccine scheme for poorer countries, following Biden's commitment to the program
- Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture
Key People/Management at BioNTech
Sean Marett
Chief Business and Chief Commercial Officer
Ugur Sahin
Chief Executive Officer
Sierk Poetting
Chief Financial Officer and Chief Operating Officer
Ryan Richardson
Chief Strategy Officer
Ozlem Tureci
Chief Medical Officer
Richard Gaynor
President of BioNTech US and Chief of R&D
BioNTech Office Locations
BioNTech has offices in Mainz, Halle (Saale), Idar-Oberstein, Marburg and in 4 other locations
Mainz, DE (HQ)
An der Goldgrube 12
Halle (Saale), DE
Weinbergweg 23
Idar-Oberstein, DE
Vollmersbachstraße 66
Marburg, DE
Emil-von-Behring-Straße 76
Neuried, DE
Forstenrieder Str. 8
Planegg, DE
Am Klopferspitz 19a
BioNTech Financials and Metrics
BioNTech Revenue
BioNTech's revenue was reported to be €1.99 m in FY, 2019
| EUR | |
|---|---|
Revenue (FY, 2019) | 2.0m |
Gross profit (FY, 2019) | (15.4m) |
Gross profit margin (FY, 2019), % | (774.6%) |
Net income (FY, 2019) | (179.2m) |
EBIT (FY, 2019) | (181.5m) |
Market capitalization (22-Jan-2021) | 21.0b |
Closing stock price (22-Jan-2021) | 88.0 |
Cash (31-Dec-2019) | 519.1m |
BioNTech's current market capitalization is €21 b.
Annual
| EUR | FY, 2017 |
|---|---|
Debt/Equity | -1.1 x |
Debt/Assets | 0.1 x |
Financial Leverage | -7.8 x |
BioNTech Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Apta IT | ||
| BioNTech Austria Beteiligungen GmbH | ||
| BioNTech Business Services | ||
| BioNTech Cell & Gene Therapies | ||
| BioNTech Diagnostics | ||
| BioNTech Innovative Manufacturing Services | ||
| BioNTech Protein Therapeutics | ||
| BioNTech Real Estate GmbH & Co. KG | ||
| BioNTech Real Estate Verwaltungs | ||
| BioNTech Research and Development |
BioNTech Revenue Breakdown
BioNTech revenue breakdown by business segment: 20.2% from Other Sales Transactions and 79.8% from Collaboration Revenue
BioNTech Cybersecurity Score
BioNTech Online and Social Media Presence
36.95k Twitter followers
BioNTech has 36.95k Twitter Followers. The number of followers has increased 12.7% month over month and increased 73.7% quarter over quarter
BioNTech's Trends
Twitter Engagement Stats for @BioNTech_Group
104
Tweets
171
Following
36.9k
Followers
4
Tweets last 30 days
659
Avg. likes per Tweet
100%
Tweets with engagement
BioNTech News and Updates
January 22, 2021
BioNTech, Pfizer to sell 40 million doses to lower-income countries
BioNTech SE and Pfizer Inc. said Friday that they plan to sell 40 million doses of their COVID-19 vaccine this year to Covax, a group that aims to ensure 92 lower-income countries have access to coronavirus vaccines. BioNTech's stock gained 1.2% in trading on Friday, while shares of Pfizer were up…
January 22, 2021
Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19
NEW YORK CITY, NY and MAINZ, GERMANY, January 22, 2021 (GLOBE NEWSWIRE) — Pfizer and BioNTech SE today announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COVID-19 Vaccine. The doses will be delivered throughout 2021.
January 22, 2021
Pfizer and BioNTech will reportedly supply COVID-19 shots to COVAX, the WHO's vaccine scheme for poorer countries, following Biden's commitment to the program
Summary List PlacementPfizer and BioNTech will supply COVID-19 vaccines to COVAX, the World Health Organization (WHO) scheme designed to share doses with poorer countries, two sources with knowledge of the matter told Reuters.
The number of doses Pfizer and BioNTech share with the scheme would lik…
January 20, 2021
Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture
New York and Mainz, Germany, January 20, 2021 — Today, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine BNT162b2 to neutralize t…
January 20, 2021
Pfizer, BioNTech Shot Likely to Defeat Mutant, New Study Shows
Pfizer, BioNTech Shot Likely to Defeat Mutant, New Study Shows
January 14, 2021
BioNTech Billionaires Back Startup Trying to Keep Trains on Time
BioNTech Billionaires Back Startup Trying to Keep Trains on Time
BioNTech Blogs
November 29, 2020
HCP 3 Role of Vaccines in Pandemic
HCP 3 Role of Vaccines in Pandemic
admin
Sun, 11/29/2020 - 20:09
November 29, 2020
HCP 5 Biontechs Sars-Cov-2 Vaccine Candidates
HCP 5 Biontechs Sars-Cov-2 Vaccine Candidates
admin
Sun, 11/29/2020 - 20:09
November 29, 2020
HCP 4 Technology Platforms for COVID-19 vaccines
HCP 4 Technology Platforms for COVID-19 vaccines
admin
Sun, 11/29/2020 - 20:09
BioNTech Frequently Asked Questions
When was BioNTech founded?
BioNTech was founded in 2008.
Who are BioNTech key executives?
BioNTech's key executives are Sean Marett, Ugur Sahin and Sierk Poetting.
How many employees does BioNTech have?
BioNTech has 1,300 employees.
What is BioNTech revenue?
Latest BioNTech annual revenue is €2 m.
What is BioNTech revenue per employee?
Latest BioNTech revenue per employee is €1.5 k.
Who are BioNTech competitors?
Competitors of BioNTech include Kite Pharma, 3sbio and Evotec.
Where is BioNTech headquarters?
BioNTech headquarters is located at An der Goldgrube 12, Mainz.
Where are BioNTech offices?
BioNTech has offices in Mainz, Halle (Saale), Idar-Oberstein, Marburg and in 4 other locations.
How many offices does BioNTech have?
BioNTech has 8 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies